Stratatech's genetically engineered skin tissue kills drug-resistant bacteria in mice - UPDATE
This article was originally published in Clinica
Artificial skin grafts produced by regenerative medicine firm Stratatech have been shown to dramatically reduce bacterial infection, following genetic modification of the cells from which they are composed. The skin substitute product, which is based on the firm's core technology, StrataGraft, is efficacious against pathogen species that cannot be killed by antibiotics.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.